{"id":{"repo_id":"vcu","oai_identifier":"oai:scholarscompass.vcu.edu:etd-9701"},"canonical_url":"https://search.ndltd.org/etd/vcu/oai:scholarscompass.vcu.edu:etd-9701","repository":{"repo_id":"vcu","name":"Virginia Commonwealth University","base_url":"https://scholarscompass.vcu.edu/do/oai/"},"display":{"title":"COST-EFFECTIVENESS ANALYSIS OF DIRECT-ACTING ANTIVIRAL STRATEGIES FOR HEPATITIS C POSITIVE DONOR TO NEGATIVE RECIPIENT KIDNEY TRANSPLANTATION","abstract":"<p><strong>Background. </strong>Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short <strong>D</strong>irect acting <strong>A</strong>nti-viral <strong>P</strong>rophylaxis to <strong>P</strong>r<strong>e</strong>vent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant <strong>R</strong>ecipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies.</p> <p><strong>Methods. </strong>We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration.</p> <p><strong>Results. </strong>Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient.</p> <p><strong>Conclusions. </strong>Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations.</p>","abstract_html":"&lt;p&gt;&lt;strong&gt;Background. &lt;/strong&gt;Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short &lt;strong&gt;D&lt;/strong&gt;irect acting &lt;strong&gt;A&lt;/strong&gt;nti-viral &lt;strong&gt;P&lt;/strong&gt;rophylaxis to &lt;strong&gt;P&lt;/strong&gt;r&lt;strong&gt;e&lt;/strong&gt;vent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant &lt;strong&gt;R&lt;/strong&gt;ecipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Methods. &lt;/strong&gt;We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Results. &lt;/strong&gt;Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Conclusions. &lt;/strong&gt;Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations.&lt;/p&gt;","abstract_has_math":true,"creators":["Yakubu, Idris","https://orcid.org/0000-0002-7871-3479"],"institution":null,"degree_name":"Master of Science","degree_level":"Thesis","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Vasco Pontinha"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T09:16:30Z","subjects":["cost-effectiveness analysis","hepatitis C","kidney transplantation","direct-acting antiviral","prophylaxis","glecaprevir/pibrentasvir","sofosbuvir/velpatasvir","Pharmacoeconomics and Pharmaceutical Economics"],"languages":[],"rights":["© The Author"],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://scholarscompass.vcu.edu/etd/8509","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://scholarscompass.vcu.edu/etd/8509","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://scholarscompass.vcu.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ascholarscompass.vcu.edu%3Aetd-9701","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Vasco Pontinha"]},{"key":"dc:creator","label":"Author","values":["Yakubu, Idris","https://orcid.org/0000-0002-7871-3479"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-10-16T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2026-01-01T08:00:00Z"]},{"key":"dc:date.submitted","label":"Dc Date Submitted","values":["2026-10-16T07:00:00Z"]},{"key":"dc:relation.ispartof","label":"Dc Relation Ispartof","values":["VCU University Archives","VCU Theses and Dissertations"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cost-effectiveness analysis","hepatitis C","kidney transplantation","direct-acting antiviral","prophylaxis","glecaprevir/pibrentasvir","sofosbuvir/velpatasvir","Pharmacoeconomics and Pharmaceutical Economics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["© The Author"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholarscompass.vcu.edu/etd/8509"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p><strong>Background. </strong>Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short <strong>D</strong>irect acting <strong>A</strong>nti-viral <strong>P</strong>rophylaxis to <strong>P</strong>r<strong>e</strong>vent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant <strong>R</strong>ecipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies.</p> <p><strong>Methods. </strong>We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration.</p> <p><strong>Results. </strong>Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient.</p> <p><strong>Conclusions. </strong>Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations.</p>","Background. Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short Direct acting Anti-viral Prophylaxis to Prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant Recipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies. Methods. We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration. Results. Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient. Conclusions. Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations."]},{"key":"dc:title","label":"Title","values":["COST-EFFECTIVENESS ANALYSIS OF DIRECT-ACTING ANTIVIRAL STRATEGIES FOR HEPATITIS C POSITIVE DONOR TO NEGATIVE RECIPIENT KIDNEY TRANSPLANTATION"]}]}],"canonical_facts":{"dc:contributor":["Vasco Pontinha"],"dc:creator":["Yakubu, Idris","https://orcid.org/0000-0002-7871-3479"],"dc:date.available":["2026-10-16T07:00:00Z"],"dc:date.created":["2026-01-01T08:00:00Z"],"dc:date.submitted":["2026-10-16T07:00:00Z"],"dc:description.abstract":["<p><strong>Background. </strong>Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short <strong>D</strong>irect acting <strong>A</strong>nti-viral <strong>P</strong>rophylaxis to <strong>P</strong>r<strong>e</strong>vent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant <strong>R</strong>ecipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies.</p> <p><strong>Methods. </strong>We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration.</p> <p><strong>Results. </strong>Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient.</p> <p><strong>Conclusions. </strong>Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations.</p>","Background. Short-duration direct-acting antiviral (DAA) administration achieves sustained virologic response in hepatitis C virus (HCV)-positive donor to negative recipient (D+/R−) kidney transplants; however, the cost-effectiveness of the DAA strategies has not been comprehensively evaluated using contemporary real-world transmission data and the most recent drug pricing. We sought to determine the most cost-efficient DAA strategy using data from the Ultra-short Direct acting Anti-viral Prophylaxis to Prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant Recipients (DAPPeR) trial experience of 204 consecutive D+/R− kidney transplants and current drug acquisition costs, comparing it to other published strategies. Methods. We developed a decision model to estimate the cost-effectiveness of several DAA strategies from the perspective of the health system. In this analysis, we compared 5 DAA strategies: (1) 7-day sofosbuvir/velpatasvir (SOF/VEL); (2) 8-day glecaprevir/pibrentasvir (G/P); (3) 4-week SOF/VEL; (4) 8-week G/P transmit-and-treat; and (5) 14-day G/P regimen. Drug costs were informed by wholesale acquisition cost (WAC) minus an assumed 30% institutional discount. Transition probabilities were derived from published clinical trials and the expanded DAPPeR study of 204 consecutive D+/R− kidney transplants. The outcome was defined as no HCV infection after each respective DAA administration. Results. Strategy 2 (8-day G/P) was the least costly intervention (EEC: $2,640) with a 100% success rate, followed by Strategy 1 (7-day SOF/VEL; EEC: $5,273), Strategy 5 (14-day G/P; EEC: $5,544), Strategy 3 (4-week SOF/VEL; EEC: $5,600), and Strategy 4 (8-week G/P transmit-and-treat; EEC: $18,480). All short-duration treatment strategies were substantially less expensive than transmit-and-treat, with savings ranging from $12,880 to $15,840 per transplanted patient. Conclusions. Short-duration DAA using 8-day G/P or 7-day SOF/VEL is the most cost-effective approach for HCV D+/R− kidney transplants. The choice between these strategies is sensitive to institution-specific drug pricing and real-world transmission rates, underscoring the need for individualized economic evaluations."],"dc:identifier":["https://scholarscompass.vcu.edu/etd/8509"],"dc:relation.ispartof":["VCU University Archives","VCU Theses and Dissertations"],"dc:rights":["© The Author"],"dc:subject":["cost-effectiveness analysis","hepatitis C","kidney transplantation","direct-acting antiviral","prophylaxis","glecaprevir/pibrentasvir","sofosbuvir/velpatasvir","Pharmacoeconomics and Pharmaceutical Economics"],"dc:title":["COST-EFFECTIVENESS ANALYSIS OF DIRECT-ACTING ANTIVIRAL STRATEGIES FOR HEPATITIS C POSITIVE DONOR TO NEGATIVE RECIPIENT KIDNEY TRANSPLANTATION"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-11-19T09:16:30Z"}